Breaking News: ImmuneOncia’s CD47 Antibody Shows Promising Results in Phase 1 Trial at ESMO 2023!
Exciting News in Cancer Research at ESMO 2023 IMC-002 Clinical Trial Results Announced in Madrid SEOUL, South Korea–(BUSINESS WIRE)–ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European Society for Medical Oncology (ESMO 2023) held in Madrid, Spain…